Context Therapeutics Inc. (CNTX) — SEC Filings
Context Therapeutics Inc. (CNTX) — 42 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 20 8-K, 6 10-Q, 6 SC 13G.
View Context Therapeutics Inc. on SEC EDGAR
Overview
Context Therapeutics Inc. (CNTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: On April 2, 2026, Context Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing includes an exhibit, EX-99.1, titled 'a04022026fasttrackdesignat.htm', and various XBRL documents.
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral, 2 mixed. The dominant filing sentiment for Context Therapeutics Inc. is neutral.
Filing Type Overview
Context Therapeutics Inc. (CNTX) has filed 20 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 5 SC 13G/A, 6 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of CNTX's 30 recent filings, 4 were flagged as high-risk, 8 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$9,693,237 |
| EPS | -$0.10 |
| Debt-to-Equity | 0.08 |
| Cash Position | $76,938,183 |
| Operating Margin | N/A |
| Total Assets | $79,231,160 |
| Total Debt | $6,056,994 |
Key Executives
- Philadelphia, Pennsylvania
- Martin Lehr
- Alex Levit
- Jennifer Minai Azary
- Claudio Dansky Ullman, MD
- Jonathan T. Raper
Industry Context
Context Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focused on developing novel therapeutics. Success is heavily dependent on clinical trial outcomes, regulatory approvals, and effective commercialization strategies. The industry is characterized by significant R&D investment, long development cycles, and the potential for high returns but also substantial risk.
Top Tags
filing (6) · material-agreement (6) · 10-Q (5) · financials (4) · 8-K (3) · corporate-governance (3) · Biotechnology (2) · Clinical Stage (2) · Oncology (2) · other-events (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| iXBRL 8-K Size | 25511 | Size of the main 8-K document in bytes. |
| EX-99.1 Size | 11745 | Size of the exhibit EX-99.1 in bytes. |
| Net loss for Q3 2025 | $9.69M | Decreased from $17.46M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $23.10M | Slightly decreased from $23.38M in 2024 |
| Research and development expenses for Q3 2025 | $8.72M | Decreased from $16.83M in Q3 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $76.94M | Sufficient to fund operations for at least 12 months |
| Accumulated deficit as of Sept 30, 2025 | $117.9M | Indicates significant historical losses |
| Common shares outstanding as of Nov 4, 2025 | 91,879,177 | Increased from 89,704,194 at Dec 31, 2024 |
| Cash used in operating activities for nine months ended Sept 30, 2025 | $17.44M | Increased from $9.65M in 2024, indicating higher cash burn |
| Revenue | $0 | No revenue for Q2 2025 and YTD 2025, indicating a pre-commercial stage. |
| Net Loss (Q2 2025) | $7.5M | Represents a decrease from $8.2M in Q2 2024, showing improved expense management. |
| Net Loss (YTD 2025) | $15.1M | Represents a decrease from $16.5M in YTD 2024, reflecting a slower burn rate. |
| Period End Date | 2025-06-30 | The reporting period for the 10-Q filing. |
| SEC File Number | 001-40654 | Unique identifier for Context Therapeutics' SEC filings. |
| Fiscal Year End | 1231 | Indicates the end of the company's annual accounting period. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Context Therapeutics Inc. (CNTX)?
Context Therapeutics Inc. has 42 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 6 10-Q, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CNTX filings?
Across 42 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 37 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Context Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Context Therapeutics Inc. (CNTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Context Therapeutics Inc.?
Key financial highlights from Context Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CNTX?
The investment thesis for CNTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Context Therapeutics Inc.?
Key executives identified across Context Therapeutics Inc.'s filings include Philadelphia, Pennsylvania, Martin Lehr, Alex Levit, Jennifer Minai Azary, Claudio Dansky Ullman, MD and 1 others.
What are the main risk factors for Context Therapeutics Inc. stock?
Of CNTX's 30 assessed filings, 4 were flagged high-risk, 8 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Context Therapeutics Inc.?
Forward guidance and predictions for Context Therapeutics Inc. are extracted from SEC filings as they are enriched.